Hubei Guangji Pharmaceutical Co., Ltd.

Equities

000952

CNE0000010R5

Pharmaceuticals

End-of-day quote Shenzhen S.E. 23:00:00 29/04/2024 BST 5-day change 1st Jan Change
5.9 CNY +2.97% Intraday chart for Hubei Guangji Pharmaceutical Co., Ltd. +15.46% -26.16%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Guangji Pharmaceutical Gets Nod to Produce Entecavir MT
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Guangji Pharma to Establish Joint Innovation Laboratory With Jiangnan University MT
Guangji Pharma to Borrow 281 Million Yuan From Bank to Support Acquisition Deals MT
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hubei Guangji Pharmaceutical Announces Profit Distribution Proposal for 2022 CI
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Guangji Pharma Registers Diabetes-Related Infection Drug MT
Hubei Guangji Pharma to Invest 468 Million Yuan in Parkson Biotechnology Amid Bankruptcy Reorganization MT
Hubei Guangji Pharma Signs 6MW Solar Power Project MT
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Guangji Pharmaceutical Unit to Resume Production After Three-Month Stoppage MT
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Hubei Guangji Pharmaceutical Jikang Medicine Co., Ltd. announced that it has received CNY 45 million in funding from Hubei Guangji Pharmaceutical Co., Ltd. CI
Hubei Guangji Pharmaceutical Co., Ltd. Announces Cash Dividend on A Shares for the Year 2021, Payable on May 27, 2022 CI
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Hubei Guangji Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021 CI
Hubei Guangji Pharmaceutical Co., Ltd. Announces the Profit Distribution Proposal for the Year 2021 CI
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Guangji Pharmaceutical Co. Ltd. announced that it has received CNY 180 million in funding from Hubei Guangji Pharmaceutical Co., Ltd. CI
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Hubei Guangji Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Chart Hubei Guangji Pharmaceutical Co., Ltd.
More charts
Hubei Guangji Pharmaceutical Co., Ltd. is the Chinese leader of pharmaceutical ingredients production. The group's activity is organized around four product families: - vitamins: riboflavin and beta carotene; - food supplements; - fine chemistry products; - medicinal preparations.
Calendar
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 000952 Stock
  4. News Hubei Guangji Pharmaceutical Co., Ltd.
  5. Guangji Pharmaceutical Unit to Resume Production After Three-Month Stoppage